gbola amusa md cfa head hc research
sale trade et
viral news genet medicin pi/ii mp ii piii
highlight week decemb decemb buy chardan top pick
announc interim data cohort phase i/ii trial gene therapi gt
mucopolysaccharidosi type ii mp ii patient dose intracistern administr
gc/g brain mass result show reduct baselin csf level key biomark heparin sulfat
week patient week patient patient addit
patient progress beyond week patient dose month age show normal neurocognit
develop patient dose month age show neurocognit stabil take interim data
posit use see better result younger patient diseas neurocognit declin sma
type alreadi begun dose escal cohort cohort gc/g brain mass
buy report rnai therapeut lumasiran met primari secondari endpoint
phase illuminate-a studi primari hyperoxaluria type primari endpoint urinari oxal
excret averag month glycol oxidas go -target asset led signific reduct urinari
oxal level rel placebo alnylam plan file nda fda ema
buy announc biomark data cohort patient receiv biopsi
phase i/ii ignit dmd studi gt duchenn muscular dystrophi dmd patient
receiv dose vg/kg immunofluoresc muscl fiber microdystrophin-
posit patient dose ignit dmd studi posit patient dose western blot
express level normal patient dose normal patient dose though
previous report sae experi patient dose studi fulli resolv clinic hold announc
novemb still place solid report work determin path resum dose novarti
unrat announc global manag access program map distribut free charg dose
gt zolgensma spinal muscular atrophi patient countri zolgensma yet approv
novarti start long-term commit addit dose ad roll six-month basi
note dose repeat yearli repres roughli million demand billion npv valu
societi us sustain solut question around zolgensma access patient around globe
look forward decemb decemb happi holiday
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
gene express ring therapeut turn virom new gt vector
flagship pioneer ventur capit firm announc decemb launch ring privat
develop first-in-class gene therapi use new viral vector platform base groundbreak work
human commens virom ring probe human virom virus non-pathogen non-immunogen
demonstr favor tissu tropism abl express desir transgen offer potenti redos
short compani seek altern current predominantli aav-bas deliveri vector virom may fertil
hunt ground vector particularli light evid support exist array natur occur
commens least minim pathogen virus persist human host harm effect idea
familiar us sinc aav ubiquit commens mammal though littl disclos ring base
pleas refer import disclosur inform regul analyst certif found page report
initi work member anelloviru famili latin anellu ring group ubiquit small genet
divers virus character persist possibl lifelong non-pathogen infect
need new gene deliveri method whether viral non-vir clear sever compet technolog
develop given preced aav natur occur commens anellovirus us
reason vector explor provid immun respons remain mute follow exposur therapeut dose
viru howev advanc approach engin discov new gene deliveri vector overwhelmingli
focus aav molecular therapeut privat employ direct evolut strategi select aav vector
favor characterist current advanc preclin stage asset fabri diseas cystic fibrosi duchenn
muscular dystrophi sever ophthalmolog indic luminari georg church harvard univers
colleagu novemb publish result comprehens mutagenesi aav capsid work use
machine-guid design construct novel capsid professor church co-found privat
leverag machin learn design construct novel aav-bas capsid askbio privat develop chimer
vector natur occur serotyp advanc clinic preclin asset pomp diseas limb-girdl
muscular dystrophi type parkinson diseas indic stridebio structur inspir design
approach gener uniqu aav capsid design address issu pre-exist neutral antibodi
buy anoth phase studi success rais pt decemb naka
announc posit top-line data phase illuminate-a studi rnai therapeut
lumasiran primari hyperoxaluria type lumasiran met primari efficaci endpoint percent chang
baselin rel placebo urinari oxal excret averag across month safeti
asset demonstr encourag safeti toler profil
trial result follow recent compani achiev includ earlier-than-expect approv rnai
therapeut givlaari acut hepat porphyria posit result phase trial inclisiran
increas price target base pipelin updat model
buy reduc hs level mp ii cohort dose start decemb amusa
chardan top pick announc interim data cohort phase i/ii trial
gt mucopolysaccharidosi type ii mp ii data show consist sustain
reduct csf level heparin sulfat hs correl sever mp ii week earli sign
neurocognit stabil normal develop drug-rel seriou advers event
data us posit progress neurocognit result cohort and/or addit hs level
reduct and/or better neurocognit result cohort could program contribut regenxbio
trade bn rang seen innov post-poc aav-bas gt compani target interest market
buy aav-gadwhi may conserv npv/sh po decemb amusa
meiragtx buy chardan top pick host aav-gad parkinson diseas day present
webcast featur reason includ relat publish phase ii data meira
gt could solut patient deep brain stimul db current standard care
expect meira open ind aav-gad ahead improv regulatori visibl
cite reason aav-gad estim may conserv
 aav-gad cell gt meet primari efficaci endpoint random blind multi-cent pd trial
 aav-gad efficaci support relev object imag biomark data
 efficaci signal consist publish phase trial phase ii trial
 aav-gad gener data formid barrier exist
 practition train db would requir minim train aav-gad gt surgeri
 aav-gad present sever potenti advantag highli effect highli under-util db
 aav-gad repres non-dopaminerg strategi potenti autoregul diseas modif
 gt would avoid non-adher issu seen high number pd patient
 treatment even patient aav-gad could bn asset us alon
genet medicin news decemb decemb
vivet privat publish aav-bas gt decemb
buy announc unrat exercis option rnai therapi decemb
page
rgl unrat announc partial clinic hold lift pi trial oligo adpkd decemb
unrat announc appoint jennif cook board director decemb
nk unrat announc result pib trial off-the-shelf antibody-target nk cell tnbc decemb
buy announc file initi pi trial rnai-tx aro-hsd liver diseas decemb
unrat announc discontinu oligonucleotid suvodirsen dmd decemb
buy announc receipt prime design fanconi anemia decemb
unrat announc data pi/ii trial aav-bas phenylketonuria decemb
announc clinic data phase i/ii phenix trial aavhsc-bas gene therapi
phenylketonuria pku decemb patient receiv low dose mid dose
patient low dose cohort show reduct pku biomark phenylalanin signal
activ observ mid-dos patient specif patient experienc reduct phenylalanin level
week increas phenylalanin metabolit tyrosin week
reduct phenylalanine/tyrosin ratio week baselin
safeti teae sae report first-in-human use aavhsc trial design enabl
escal high-dos cohort expans mid-dos level upon data review
addit updat studi anticip compani pku space includ biomarin
unrat announc file clinic trial applic gt bmn uk medicin
healthcar product regulatori agenc mhra buy complet bridg studi solid
formul synthet biolog plan initi phase ii trial
unrat announc plan submit ind aav-bas gene therapi
buy announc receipt ema odd rnai-tx defici decemb
unrat host day new york citi provid updat pipelin program decemb
buy announc updat sponsor research agreement ohsu decemb
unrat announc retain right relat aso akcea-apociii-lrx decemb
unrat announc appoint ann prener board director decemb
buy announc biomark data pi/ii trial gt dmd decemb
buy announc biomark data phase i/ii ignit dmd trial gene therapi
duchenn muscular dystrophi dmd evalu biopsi taken quadricep patient
dose trial month administr vg/kg show microdystrophin express
associ neuron nitric oxid synthas nno function measur immunofluoresc
muscl fiber posit microdystrophin patient posit patient
recal novemb solid announc ignit dmd trial place clinic hold
patient dose vg/kg cohort experienc seriou advers event includ complement activ
thrombocytopenia cardio-pulmonari insuffici decreas red blood cell count acut kidney injuri per
manag fda request updat patient resum normal activ assess
caus event includ patient immun respons mitig plan prevent monitor
similar event occur futur
ucla publish pre-concept zika viru vaccin pregnant macaqu decemb
unrat appoint frank bennett cso eric swayz svp research decemb
unrat appoint lynn parshal bod chair barbara yanni bod member decemb
ly fp unrat publish gt mp iiia model decemb
harvard publish mrna nanoparticle-bas restor cell model cancer decemb
unrat announc patient dose lv-base gt fabri diseas decemb
unrat announc unrat licens aso ionis-maptrx alzheim diseas decemb
oxb gb unrat extend suppli agreement nv unrat lentivir vector decemb
buy announc preliminari result aav-bas gangliosidosi decemb
page
selb unrat announc mm privat placement advanc immtor gt program decemb
selb unrat announc askbio privat exercis option licens immtor aav gt decemb
selecta bioscienc announc asklepio biopharmaceut askbio exercis option develop
commerci selecta immtor platform immun toler aav gene therapi pomp diseas
term agreement selecta may receiv mm up-front mileston payment plu royalti sale
selecta immtor program base synthet vaccin particl encapsul rapamycin svp-r
report mitig immun respons aav capsid implic immtor could reduc capsid
immunogen allow re-dos aav-bas gene therapi
qure buy publish preclin data huntington diseas decemb
gmab unrat collabor curevac develop mrna-bas therapi cancer decemb
freelin privat announc mm seri advanc gt chronic system diseas decemb
unrat announc price public offer common stock warrant decemb
privat announc cell therapi manufactur facil singapor decemb
sight fp buy announc bond financ mm capit increas mm decemb
turnston biolog privat announc collabor takeda unrat ov decemb
unrat announc prime design gt mp iiia decemb
buy announc patient dose studi rnai-therapeut aro-aat decemb
compani mention report
page
page
select catalyst genet medicin coverag
figur regenxbio rocket solid uniqur expect import data read-out
initi phase i/ii clinic trial huntington diseas
initi phase i/ii trial dmd nationwid children hospit
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
submit ind methylmalon acidemia mma
present interim data cohort steroid prophyl pi/ii studi hofh
initi dose phase trial hemophilia
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
present preclin data new gt program fabri pomp defici
file ind cta pomp diseas
provid updat phase i/ii studi hemophilia
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
page
select catalyst outsid genet medicin coverag
initi phase ib trial beta-thalassemia
initi clinic trial charcot-marie-tooth type
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
file ind inherit amyotroph later sclerosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
file ind gangliosidosi
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl buy
figur select price movement week end dec vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm appli genet therapytickerratingccm ptupsideclosechang changemc mm arbutu gene editingtickerratingccm ptupsideclosechang changemc mm precis pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid technolog pharmaceut
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis feldan recombinet trucod gene repair verv technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
ultragenyx genetx
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
